Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
Breadcrumb Trail Links GlobeNewswire Author of the article: Published Nov 26, 2024 • 15 minute read Article content AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) …